iX Biopharma Ltd. (SGX:42C)
Singapore · Delayed Price · Currency is SGD 0.5000
+0.0350 (7.53%)
At close: Oct 29, 2026
iX Biopharma Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, iX Biopharma stock has a consensus rating of "Strong Buy" and an average price target of $1.09. The average 1-year stock price forecast is 117.00% higher than the current stock price, while the lowest is $1.00 (+100.00%) and the highest is $1.17 (+134.00%).
Price Target: $1.09 (+117.00%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for iX Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|
| Strong Buy | 1 | 1 | 2 |
| Buy | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst OCBC Investment No rating | OCBC Investment | Buy Maintains $0.92 | Buy | Maintains | $0.92 | +84.00% | Oct 26, 2026 |
Unknown Analyst KGI Securities No rating | KGI Securities | Buy Maintains $1.17 | Buy | Maintains | $1.17 | +134.00% | Oct 13, 2026 |
| Phillip Securities | Phillip Securities | Buy Maintains $1.00 | Buy | Maintains | $1.00 | +100.00% | Sep 8, 2026 |
Financial Forecast
Revenue This Year
17.79M
from 6.85M
Increased by 159.58%
Revenue Next Year
54.21M
from 17.79M
Increased by 204.74%
EPS This Year
-0.01
EPS Next Year
0.00
from -0.01
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is SGD.